Replimune price target raised to $27 from $18 at BMO Capital

BMO Capital analyst Evan Seigerman raised the firm’s price target on Replimune (REPL) to $27 from $18 and keeps an Outperform rating on the shares. The positive share reaction to Replimune’s RP1 BLA acceptance reflects the removal of a key overhang to shares, with a PDUFA set for July 22, 2025, also removing doubt on whether the company’s data package was sufficient for submissions, the analyst tells investors in a research note. Replimune’s IGNYTE-3 confirmatory trial is also now well underway, with management planning to enroll over 100 sites globally, the firm added.